J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

Mr Rajarshi (Rishi) Mukherjee, a Ronald Finn Senior Research Fellow has become the first recipient of the prestigious Medical ...

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold.

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

In an exclusive interview with SheKnows, Sheryl Lee Ralph spoke about the importance of health discussions with your family!

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-12-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2062.30. On previous day, the ...